BioNanoScience, Journal Year: 2024, Volume and Issue: 15(1)
Published: Dec. 23, 2024
Language: Английский
Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106623 - 106623
Published: Jan. 1, 2025
Citations
2
International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 278, P. 134962 - 134962
Published: Aug. 22, 2024
Language: Английский
Citations
9
Materials Today Bio, Journal Year: 2025, Volume and Issue: 31, P. 101457 - 101457
Published: Jan. 5, 2025
Central nervous system (CNS) diseases are a major cause of disability and death worldwide. Due to the blood-brain barrier (BBB), drug delivery for CNS is extremely challenging. Nano-delivery systems can overcome limitations BBB deliver drugs CNS, improve ability target brain provide potential therapeutic methods diseases. At same time, choice different (bypassing or crossing BBB) further optimize effect nano-drug system. This article reviews nano-delivery way enters brain. Different kinds nanoparticles were discussed in depth.
Language: Английский
Citations
1
BMC Chemistry, Journal Year: 2025, Volume and Issue: 19(1)
Published: March 8, 2025
Solidified reverse micellar technology and surface-modification are promising techniques for improving the biopharmaceutical properties of poorly water-soluble drugs such as artemether, a first-line antimalarial drug. Thus, aim this study was to develop evaluate artemether-loaded chitosan-coated solid lipid nanoparticles (SLNs) based on solidified solution (SRMS) improved oral malaria therapy. Artemether-loaded unloaded SLNs were prepared from optimized SRMS (consisting Phospholipon® 90G Compritol® ATO 888 at 3:7 ratio) with or without chitosan by high-shear melt-homogenization, thereafter characterized physicochemical performance, stability, safety activity using Plasmodium berghei-infected mice. Results showed both smooth irregular particles layer polymer coating in chitosan-modified SLNs, increased drug amorphization well compatibility excipients employed formulations. The formulation stable nanomeric (size 292.90 ± 5.01 nm, polydispersity index 0.191 0.09, zeta-potential + 32.50 1.58 mV) good encapsulation efficiency (82.03%), demonstrated minimal toxicity Caco-2 cells, exhibited controlled release compared fast artemether suspension gave significantly (p < 0.05) greater than suspension. SRMS-based can be pursued novel alternative treatment.
Language: Английский
Citations
1
Journal of Dispersion Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 33
Published: April 28, 2025
Language: Английский
Citations
1
Neurochemical Research, Journal Year: 2024, Volume and Issue: 50(1)
Published: Nov. 22, 2024
Abstract Exposure to rotenone results in similar pathophysiological features as Parkinson’s disease. Inflammation and oxidative stress are essential PD pathogenesis. Maresin-1 has potent anti-inflammatory properties promotes the regression of inflammation function. The current study aimed evaluate protective effects (MaR1) (ROT)-induced whether this role is associated with initiation Janus kinase (JAK)-signal transducers activator transcription (STAT) signaling pathway. Thirty male Wister rats were classified into control, ROT-treated, ROT + MaR1-treated groups. Rats underwent rotarod, open field, grip strength, stepping tests part their motor behavioral evaluation. Serum glial cell-derived neurotrophic factor (GDNF) striatal dopamine, acetylcholine, malondialdehyde (MDA), reduced glutathione (GSH), TNF-α, IL-6, IL-1β evaluated. Expression JAK1 STAT3 genes was assessed striatum. Then, tissue subjected histological immunohistochemical evaluation for caspase-3, GFAP, NF-kB. administrated group showed significant impairment. This accompanied by levels GDNF dopamine increased well augmented inflammatory biomarkers antioxidant activity. Inflammatory pathways (JAK1/STAT3, NF-kB) upregulated. Histopathological changes upregulation GFAP immunopositive reaction observed. Remarkably, MaR1 treatment effectively alleviated behavior, histopathological changes, biochemical alterations induced ROT. exerts against ROT-induced its anti-inflammatory, antiapoptotic, properties. mechanisms action may involve modulation such JAK/STAT.
Language: Английский
Citations
4
BioNanoScience, Journal Year: 2025, Volume and Issue: 15(2)
Published: Feb. 12, 2025
Language: Английский
Citations
0
International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 144497 - 144497
Published: May 1, 2025
Language: Английский
Citations
0
International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 12343 - 12368
Published: Nov. 1, 2024
The intranasal (IN) route of drug delivery can effectively penetrate the blood-brain barrier and deliver drugs directly to brain for treatment central nervous system (CNS) disorders via intra-neuronal or extra-neuronal pathways. This approach has several advantages, including avoidance first-pass metabolism, high bioavailability, ease administration, improved patient compliance. In recent years, an increasing number studies have been conducted using encapsulated in solid lipid nanoparticles (SLNs) nanostructured carriers (NLCs), delivering them IN pathway. SLNs are first-generation nanocarriers, known their excellent biocompatibility, drug-loading capacity, remarkable stability. NLCs, regarded as second-generation SLNs, not only retain advantages but also exhibit enhanced stability, preventing leakage during storage. this review, we examined vivo between 2019 2024 that used NLCs address CNS route. By statistical methods evaluate pharmacokinetic parameters, found markedly accumulation targeting within brain. Additionally, pharmacodynamic evaluations indicated method substantially therapeutic effectiveness alleviating symptoms rat models diseases. addition, enhancing efficacy nose-to-brain discussed, well advances clinical trials regarding NLCs.
Language: Английский
Citations
3
Drug Delivery and Translational Research, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 30, 2024
Cannabidiol (CBD) is a natural product isolated from the Cannabis sativa plant that was approved by United States Food and Drug Administration (US FDA) for treatment of resistant epilepsy. Despite its therapeutic potential, CBD's clinical application limited poor aqueous solubility low oral bioavailability. The primary aim this research to enhance bioavailability CBD developing nanostructured lipid carriers (NLCs) using conventional hot homogenization method (CHH). In current study, nine NLC formulations were developed through CHH, which, NLC5 emerged as most promising formulation, exhibiting high entrapment efficiency (99.23%), particle size 207 nm, polydispersity index 0.19, zeta potential -26 mV. Additionally, drug release testing showed rate more than 90% within 15 min, indicating an enhancement dissolving compared pure CBD. in vivo pharmacokinetic study formulation 27% Furthermore, Stability studies conducted at 4 °C 25 on over three months, revealed consistent parameters, underscoring robustness formulation. conclusion, successful CBD-loaded NLCs resulted improved rate, enhanced CBD, maintained stability, making it approach effective delivery
Language: Английский
Citations
3